All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI

May 30th 2025

Ivonescimab plus chemotherapy improved PFS vs chemotherapy alone in second- and later-line EGFR-mutated non–small cell lung cancer.

Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer

May 30th 2025

China’s NMPA approved zanidatamab for previously treated, unresectable or metastatic, HER2-positive biliary tract cancer.

ASCO 2025 Highlights: Menin Inhibitor for Acute Myeloid Leukemia; Organ Transplant and Checkpoint Inhibitors

May 30th 2025

Faculty from Roswell Park Comprehensive Cancer Center are among the experts invited to share their research findings at the 2025 ASCO Annual Meeting.

OncLive Polls Show Top Votes for Anticipated Gynecologic Cancer Abstracts at ASCO 2025

May 30th 2025

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

Encorafenib/Cetuximab Plus Chemo Boosts PFS in BRAF V600E+ mCRC

May 30th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

Fixed-Duration Bispecific Antibodies Are Effective, Safe, and Convenient for Follicular Lymphoma

May 29th 2025

Vivek Patel, MD, discusses the safety of bispecific antibodies and the choice between these agents and CAR T-cell therapy for follicular lymphoma.

Neoantigen-Reactive TILs With CISH Knockout Are Safe and Effective in Metastatic GI Tumors

May 29th 2025

CRISPR-Cas9–mediated CISH gene knockout TIL therapy was well tolerated and demonstrated early signals of efficacy in metastatic GI epithelial cancer.

Fifteen-Year Follow-Up Data Confirm Rituximab Delays the Need for New Treatment in Advanced Follicular Lymphoma

May 29th 2025

Rituximab monotherapy delayed the time to next treatment vs watchful waiting in advanced stage, asymptomatic, low tumor burden follicular lymphoma.

FDA Grants Fast Track Status to EBC-129 for Pancreatic Ductal Adenocarcinoma

May 29th 2025

EBC-129 has been awarded fast track designation from the FDA for patients with pancreatic ductal adenocarcinoma.

Can Gut Microbes Save Patients From Chemotherapy Side Effects?

May 29th 2025

Researchers at UC San Francisco discovered that some gut bacteria reduce the side effects of chemotherapy and that some drugs boost protective bacteria.

BLA Is Withdrawn for Patritumab Deruxtecan in EGFR-Mutated NSCLC

May 29th 2025

The BLA seeking the approval of patritumab deruxtecan in EGFR-mutated non–small cell lung cancer has been voluntarily withdrawn.

ORIC-944 Plus AR Inhibition Yields PSA Responses in mCRPC

May 29th 2025

The addition of ORIC-944 to an AR pathway inhibitor generated PSA responses in metastatic castration-resistant prostate cancer.

Clinical Judgment in the Provision of Optimal Care vs Selection Bias in a Survival Analysis

May 29th 2025

Maurie Markman, MD, explores the key role of clinical judgment in treatment decision-making and its impact on patient outcomes in cancer research.

Pelabresib/Ruxolitinib Improves Spleen Responses in JAK Inhibitor–Naive Myelofibrosis

May 29th 2025

The addition of pelabresib to ruxolitinib generated a significant improvement in spleen response in patients with JAK inhibitor–naive myelofibrosis.

Oncolytic Immunotherapy Approaches Open Up Alternative Treatment Avenues After Progression on Anti–PD-1 Therapy in Melanoma

May 29th 2025

Nikhil Khushalani, MD, discusses the clinical potential of RP1 plus nivolumab in patients with PD-1–refractory melanoma as well as considerations regarding its use.

FDA Grants Priority Review to Sevabertinib for HER2-Mutant NSCLC

May 28th 2025

The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.

Awareness Efforts Aim to Improve Early Recognition and Multidisciplinary Care for Brain Tumors

May 28th 2025

Ryan Merrell, MD, underscores the need for early glioma detection, advances in IDH-targeted therapy, and emerging immunotherapy in glioblastoma care.

FOLFIRINOX Significantly Improves PFS Over Gemcitabine in Locally Advanced Pancreatic Carcinoma

May 28th 2025

NEOPAN data support the superiority of FOLFIRINOX over gemcitabine in locally advanced pancreatic carcinoma.

Elotuzumab Plus PVd Has Antitumor Activity in Heavily Pretreated R/R Myeloma

May 28th 2025

Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.

New Biomarker May Guide Best Use of KRAS Inhibitors in Lung Cancer

May 28th 2025

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.